STAT News: Rush to end drug rebates may be bad for patients, payers, and pharma

STAT News: Rush to end drug rebates may be bad for patients, payers, and pharma

Rebates for drugs have worked for decades to provide a mechanism for health plans and their clients to negotiate drug prices.